|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - USD | -.--% |
|
-.--% | -.--% |
EPIRUS Biopharmaceuticals, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company's net loss was $7.5 million, or $0.39 a share, compared to a net loss of $7.6 million for the first quarter of 2014. Revenue was $25,000.
Loss from operations was $7,222,000 compared to $6,222,000 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 26 | |
| +67.53% | 63.85B | |
| -0.77% | 41.83B | |
| +45.66% | 40.65B | |
| -10.72% | 27.12B | |
| +13.30% | 26.52B | |
| -22.79% | 18.69B | |
| +4.70% | 12.73B | |
| +24.10% | 12.11B | |
| +27.41% | 12.07B |
EPIRUS BIOPHARMACEUTICALS, INC. 
